Skip to main content
Log in

Abstract

Carbamazepine seems to be as effective as phenytoin in the treatment of grand mat and psychomotor epilepsy. It is the drug of first choice in trigeminal neuralgia.

After single oral doses of carbamazepine, the absorption is fairly complete and the elimination half-life is about 35 hours (range 18 to 65 hours). During multiple dosing, the half-life is decreased to 10–20 hours, probably due to autoinduction of the oxidative metabolism of the drug. Phenytoin and barbiturates also induce the metabolism of carbamazepine. After single doses of carbamazepine, elimination follows dose-dependent first order kinetics.

Carbamazepine is metabolised by oxidation before excretion in the urine. In experimental animals, the metabolite carbamazepine-10, 11 -epoxide has anticonvulsant activity comparable with that of the parent drug. The plasma concentration of the metabolite during long-term treatment of epileptic patients varies between 5 and 81% of that of the parent drug. The plasma protein binding of the metabolite is about 50% compared with about 75% for the parent drug. Less than 50% of a given carbamazepine dose has been identified as metabolites in the urine. The quantitatively most important metabolite is the trans-10, 11-dihydro-10, 11-diol.

The kinetics of carbamazepine have been explored to some extent in pregnant women, newborns and children. Plasma levels of carbamazepine seem to decrease during pregnancy, possibly as a result of increased metabolism. The drug readily crosses the placenta and the levels measured in newborns are comparable with maternal plasma concentrations. In newborns exposed to the drug during fetal life, the plasma half-lives were relatively short (8.2 to 28.1 hours) indicating an induction of carbamazepine metabolism during gestation. The pharmacokinetics of carbamazepine in children aged 0.3 to 15 years are comparable with that in adults.

A single daily dose of carbamazepine is insufficient; 2 doses per day are appropriate in most cases, but some patients may benefit from more frequent dosing to avoid side-effects.

Compared with phenytoin, for example, very few controlled studies have been performed to establish the plasma level range of carbamazepine associated with the best therapeutic outcome. However, the best anticonvulsant effect of carbamazepine seems to be obtained at plasma levels of about 5 to 10μ/ml (20 to 40μmol/L). Side-effects are most frequent at higher levels but may also be seen at lower levels.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  • Alexanderson, B.: Pharmacokinetics of nortriptyline in man after single and multiple oral doses: the predictability of steady state plasma concentrations from single dose plasma level data. European Journal of Clinical Pharmacology 4: 82–91 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Baker. K.M.; Csetenyi, J.; Frigerio, A.; Morselli, P.L.; Parravicini, F. and Pifferi, G.: 10, 11-Dihydro-10, 11-dihydroxy-5H-dibenz [b,f] azepine-5-carboxamide: A metabolite of carbamazepine isolated from human and rat urine. Journal of Medicinal Chemistry 16: 703–705 (1973a).

    Article  PubMed  CAS  Google Scholar 

  • Baker. K.M.; Frigerio. A.; Morselli. P.L. and Pifferi, G.: Identification of a rearranged degradation product from carbamazepine-10.11-epoxide. Journal of Pharmaceutical Sciences 62: 475–476 (1973b).

    Article  PubMed  CAS  Google Scholar 

  • Blom. S.: Trigeminal neuralgia: Its treatment with a new anticonvulsant drug (G-32 883). Lancet 1: 839–840 (1962).

    Article  PubMed  CAS  Google Scholar 

  • Cereghino, J.J.; Broch, J.T.; van Meter, J.C.; Penry, J.K.; Smith, L.D. and White. B.G.: Carbamazepine for epilepsy — A controlled prospective evaluation. Neurology 24: 401–410 (1974).

    Article  PubMed  CAS  Google Scholar 

  • Cereghino, J.J.; Brock, J.T.; van Meter, J.C.; Penry, J.K.; Smith, L.D. and White, B.C.: The efficacy of carbamazepine combinations in epilepsy. Clinical Pharmacology and Therapeutics 18: 733–741 (1975).

    PubMed  CAS  Google Scholar 

  • Cereghino, J.J.; van Meter, J.C.: Brock, J.T.; Penry, J.K.; Smith, L.D. and White, B.G.: Preliminary observations of serum carbamazepine concentration in epileptic patients. Neurology 23: 357–366 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Chambers, R.E.; Homeida, M.; Hunter, K.R. and Teague, R.H.: Salivary carbamazepine concentrations. Lancet 1: 656–657 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Christiansen, J. and Dam, M.: Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy. Acta Neurologia Scandinavica 49: 543–546 (1973).

    Article  CAS  Google Scholar 

  • Christiansen, J. and Dam. M.: Drug interaction in epileptic patients; in Schneider, Janz. Gardner-Thorpe, Meinardi and Sherwin (Eds) Clinical Pharmacology of Anti-Epileptic Drugs, p.197–200 (Springer-Verlag, Berlin 1975).

    Chapter  Google Scholar 

  • Christiansen, J. and Dam, M.: Plasma and salivary levels of carbamazepine and carbamazepine-10, 11 -epoxide during pregnancy; in Gardner-Thorpe, Janz, Meinardi and Pippenger (Eds) Antiepileptic Drug Monitoring, p. 128–137 (Pitman Press, Avon, England 1977).

    Google Scholar 

  • Csetenyi, J.; Baker, K.M.; Frigerio, A. and Morselli, P.L.: Iminostilbene — a metabolite of carbamazepine isolated from rat urine. Journal of Pharmacy and Pharmacology 25: 340–341 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Dam, M.: and Christiansen, J.: Interaction of propoxyphene with carbamazepine. Lancet 2: 509 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Dam, M.; Jensen, A. and Christiansen, J.: Plasma level and effect of carbamazepine in grand mal and psychomotor epilepsy. Acta Neurologica Scandinavica, Suppl. 60: 33–38 (1975).

    Article  PubMed  CAS  Google Scholar 

  • DiSalle, E.; Pacifici, G.M. and Morselli, P.L.: Studies on the plasma protein binding of carbamazepine. Pharmacological Research Communications 6: 193–202 (1974).

    Article  CAS  Google Scholar 

  • Dravet, C.; Mesdjian, E.; Cenraud, B. and Roger, J.: Interaction between carbamazepine and triacetyloleandomycin. Lancet 1: 810–811 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Eadie, M.J.: Plasma level monitoring of anticonvulsants. Clinical Pharmacokinetics 1: 52–66 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Eadie, M.J.; Lander, C.M. and Tyrer, J.H.: Plasma drug level monitoring during pregnancy. Clinical Pharmacokinetics 2: 427–436 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Eichelbaum, M. and Bertilsson, L.: Determination of carbamazepine and its epoxide metabolite in plasma by high-speed liquid chromatography. Journal of Chromatography 103: 135–140 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Eichelbaum, M.; Bertilsson, L.; Lund, L.; Palmer, L. and Sjoqvist, F.: Plasma levels of carbamazepine and carbamazepine-10, 11-epoxide during treatment of epilepsy. European Journal of Clinical Pharmacology 9: 417–421 (1976a).

    Article  CAS  Google Scholar 

  • Eichelbaum, M.; Bertilsson, L.; Rane, A. and Sjoqvist, F.: Autoinduction of carbamazepine metabolism in man; in Richens and Woodford (Eds) Anticonvulsant Drugs and Enzyme Induction, p. 147–158 (Associated Scientific Publishers, Amsterdam 1976b).

    Google Scholar 

  • Eichelbaum, M.; Ekbom, K.; Bertilsson, L.; Ringberger, V.A. and Rane, A.: Plasma kinetics of carbamazepine and its epoxide metabolite in man after single and multiple doses. European Journal of Clinical Pharmacology 8: 337–341 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Ekbom, K.: Carbamazepine. a new symptomatic treatment for the paraesthesiae associated with Lhermitte’s sign. Zeitschrift fur Neurologie 200: 341–344 (1971).

    Article  PubMed  CAS  Google Scholar 

  • Ekbom, K.: Carbamazepine in the treatment of tabetic lightning pains. Archives of Neurology 26: 374–378 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Faigle, J.W.; Brechbuhler, S.; Feldmann, K.F. and Richter, W.J.: The biotransformation of carbamazepine; in Birkmayer (Ed) Epileptic Seizures — Behaviour — Pain, p. 127–140 (Huber, Berne 1976).

    Google Scholar 

  • Faigle, J.W. and Feldmann, K.F.: Pharmacokinetic data of carbamazepine and its major metabolites in man; in Schneider, Janz, Gardner-Thorpe, Meinardi and Sherwin (Eds) Clinical Pharmacology of Anti-Epileptic Drugs, p. 159–165 (Springer-Verlag, Berlin 1975).

    Chapter  Google Scholar 

  • Faigle, J.W.; Feldmann, K.F. and Baltzer, V.: Anticonvulsant effect of carbamazepine. An attempt to distinguish between the potency of the parent drug and its epoxide metabolite; in Gardner-Thorpe, Janz, Meinardi and Pippenger (Eds) Antiepileptic Drug Monitoring, p. 104–109 (Pitman Press, Avon, England 1977).

    Google Scholar 

  • Farghali-Hassan, Assael, B.M.; Bossi, L.; Garattini, S.; Gerna, M.; Gomeni, R. and Morselli. P.L.: Carbamazepine pharmacokinetics in young, adult and pregnant rats. Relation to pharmacological effects. Archives internationales de Phar-macodynamie et de therapie 220: 125–139 (1976).

    CAS  Google Scholar 

  • Farghali-Hassan, Assael, B.M.; Bossi, L. and Morselli, P.L.: Placental transfer of carbamazepine in the rat. Journal of Pharmacy and Pharmacology 27: 956–957 (1975).

    Article  Google Scholar 

  • Frigerio, A.; Baker, K.M. and Morselli, P.L.: Gas chromatographic-mass spectrometric studies on carbamazepine; in Costa and Holmstedt (Eds) Advances in Biochemical Psychopharmacology, vol. 7, p. 125–134 (Raven Press, New York 1973).

    Google Scholar 

  • Frigerio. A.; Cavo-Briones, M. and Belvedere, G.: Formation of stable epoxides in the metabolism of tricyclic drugs. Drug Metabolism Reviews 5: 197–218 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Frigerio, A.; Fanelli, R.; Biandrate, P.; Passerini, G.; Morselli, P.L. and Garattini, S.: Mass spectrometric characterisation of carbamazepine-10, 11-epoxide, a carbamazepine metabolite isolated from human urine. Journal of Pharmaceutical Sciences 61: 1144–1147 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Frigerio, A. and Morselli, P.L.: Carbamazepine: Biotransformation; in Penry and Daly (Eds) Advances in Neurology, vol 11, p. 295–308 (Raven Press, New York 1975).

    Google Scholar 

  • Gagneux. A.R.: The chemistry of carbamazepine; in Birkmayer (Ed) Epileptic Seizures — Behaviour — Pain, p. 120–126 (Huber, Berne 1976).

    Google Scholar 

  • Gamstorp, I.: Treatment with carbamazepine: Children; in Penry and Daly (Eds) Advances in Neurology, vol 11, p.237–246 (Raven Press, New York 1975).

    Google Scholar 

  • Gauchel, G.; Gauchel, F.D. and Birkofer, L.: A micromethod for the determination of carbamazepine in blood by high speed liquid chromatography. Zeitung der klinische Chemie und klinische Biochemie 1 1: 459–460 (1973).

    Google Scholar 

  • Gerardin, A. and Hirtz, J.: The quantitative assay of carbamazepine in biological material and its application to basic pharmacokinetic studies; in. Birkmayer (Ed) Epileptic Seizures — Behaviour — Pain, p. 151–164 (Huber, Berne 1976).

    Google Scholar 

  • Glatt, H.R.; Oesch, F.; Frigerio, A. and Garattini, S.: Epoxides metabolically produced from some known carcinogens and from some clinically used drugs: I. Differences in mutagenicity. International Journal of Cancer 16: 787–797 (1975).

    Article  CAS  Google Scholar 

  • Goenechea, S. and Hecke-Seibicke, E.: Beitrag zum Stoffwechsel von Carbamazepine. Zeitung der klinische Chemie und klinische Biochemie 10: 112–113 (1972).

    CAS  Google Scholar 

  • Gruska, H.; Beyer, K.-H.; Kubicki, S. and Schneider, H.: Klinik, Toxikologie und Therapie einer schweren Carbamazepine-Vergiftung. Archiv der Toxikologie 27: 193–203 (1971).

    Article  CAS  Google Scholar 

  • Hansen, J.M.; Siersbaek-Nielsen, K. and Skovsted, L.: Carbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man. Clinical Pharmacology and Therapeutics 12: 539–543 (1971).

    PubMed  CAS  Google Scholar 

  • Hempel, E. and Klinger, W.: Drug stimulated biotransformation of hormonal steroid contraceptives: clinical implications. Drugs 12: 442–448 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Hooper, W.D.; Dubetz, D.K.; Bochner, F.; Cother, L.M.; Smith, G.A.; Eadie, M.J. and Tyrer, J.H.: Plasma protein binding of carbamazepine. Clinical Pharmacology and Therapeutics 17: 433–440 (1975).

    PubMed  CAS  Google Scholar 

  • Hooper, W.D.; Dubetz, D.K.; Eadie, M.J. and Tyrer, J.H.: Preliminary observations on the clinical pharmacology of carbamazepine (Tegretol). Proceedings of the Australian Association of Neurologists 11: 189–198 (1974).

    PubMed  CAS  Google Scholar 

  • Hvidberg, E.F. and Dam, M.: Clinical pharmacokinetics of anticonvulsants. Clinical Pharmacokinetics 1: 161–188 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Johannessen, S.I.; Barruzzi, A.; Gomeni, R.; Strandjord, R.E. and Morselli, P.L.: Further observations on carbarnazepine and carbamazepine-10, 11-epoxide kinetics in epileptic patients; in Gardner-Thorpe, Janz, Meinardi and Pippenger (Eds) Antiepileptic Drug Monitoring, p. 110–127 (Pitman Press, Avon 1977).

    Google Scholar 

  • Johannessen, S.I.; Gerna, M.; Bakke, J.; Strandjord, R.E. and Morselli, P.L.: CSF concentrations and serum protein binding of carbamazepine and carbamazepine-10, 11-epoxide in epileptic patients. British Journal of Clinical Pharmacology 3: 575–582 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Johannessen, S.I. and Strandjord, R.E.: The concentration of carbamazepine (Tegretol) in serum and in cerebrospinal fluid in patients with epilepsy. Acta Neurologica Scandinavica 48 (Suppl. 51); 445–446 (1972).

    Google Scholar 

  • Johannessen, S.I. and Strandjord, R.E.: The influence of phenobarbitone and phenytoin on carbamazepine serum levels; in Schneider, Janz, Gardner-Thorpe, Meinardi and Sherwin (Eds) Clinical Pharmacology of Anti-epileptic Drugs, p.201–205 (Springer-Verlag, Berlin 1975).

    Chapter  Google Scholar 

  • Kupferberg, H.J.: GLC determination of carbamazepine in plasma. J. Pharm. Sci. 61: 284–286 (1972).

    Article  PubMed  CAS  Google Scholar 

  • Kuroiwa, Y. and Shibasaki, H.: Carbamazepine for tonic seizure in multiple sclerosis. Lancet 1: 116 (1967).

    Article  Google Scholar 

  • Kutt, H.: Carbamazepine: Chemistry and methods of determinations; in Penry and Daly (Eds), Advances in Neurology, vol. 11, p.249–260 (Raven Press, New York 1975).

    Google Scholar 

  • Kutt, H. and Penry, J.K.: Usefulness of blood levels of antiepileptic drugs. Archives of Neurology 31: 283–288 (1974).

    Article  PubMed  CAS  Google Scholar 

  • Levy, R.H.; Lockard, J.S.; Green, J.R.; Friel, P. and Martis, L.: Pharmacokinetics of carbarnazepine in monkeys following intravenous and oral administration. Journal of Pharmaceutical Sciences 64: 302–307 (1975a).

    Article  PubMed  CAS  Google Scholar 

  • Levy, R.H.; Pitlick, W.H.; Troupin, A.S.; Green, J.R. and Neal, J.M.: Pharmacokinetics of carbamazepine in normal man. Clinical Pharmacology and Therapeutics 17: 657–668 (1975b).

    PubMed  CAS  Google Scholar 

  • McAuliffe, J.J.; Sherwin, A.L.; Leppik, I.E.; Fayle, S.A. and Pippenger, C.E.: Salivary levels of anticonvulsants: A practical approach to drug monitoring. Neurology 27: 409–413 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Meinardi, H.: Other antiepileptic drugs — carbamazepine; in Woodbury, Penry and Schmidt (Eds) Antiepileptic Drugs, p.487–496 (Raven Press, New York 1972).

    Google Scholar 

  • Monaco, F; Riccio, A.; Benna, P.; Covacich, A.; Durelli, L.; Fantini, M.; Furlan, P.M.; Gilli, M.; Mutani, R.; Troni, W.; Gerna, M. and Morselli, P.L.: Further observation on carbamazepine plasma levels in epileptic patients — Relationships with therapeutic and side effects. Neurology 26: 936–943 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Morselli, P.L.: Carbamazepine: Absorption, distribution, and excretion; in Penry and Daly (Eds) Advances in Neurology, vol. 11, p.279–293 (Raven Press, New York 1975).

    Google Scholar 

  • Morselli, P.L.; Baruzzi, A.; Gerna, M.; Bossi, L. and Porta, M.: Carbamazepine and carbamazepine-10, 11-epoxide concentrations in human brain. British Journal of CUnical Pharmacology 4: 535–540 (1977).

    Article  CAS  Google Scholar 

  • Morselli, P.L.; Biandrate, P.; Frigerio, A.; Gerna, M. and Tognoni, G.: Gas chromatographic determination of carbamazepine and carbamazepine-10, 11 -epoxide in human body fluids, in Meijer, Meinardi, Gardner-Thorpe and van der Kleijn (Eds) Methods of Analysis of Anti-epileptic Drugs, p.169–175 (Excerpta Medica, Amsterdam 1973).

  • Morselli, P.L.; Bossi, L. and Gerna, M.: Pharmacokinetic studies with carbamazepine in epileptic patients; in Birkmayer (Ed) Epileptic Seizures — Behaviour — Pain, p.141–150 (Huber, Berne 1976).

    Google Scholar 

  • Morselli, P.L.; Gerna, M. and Garattini, S.: Carbamazepine plasma and tissue levels in the rat. Biochemical Pharmacology 20: 2043–2047 (1971).

    Article  PubMed  CAS  Google Scholar 

  • Morselli, P.L.; Gerna, M.; de Maio, D.; Zanda, G.; Viani, F. and Garattini, S.: Pharmacokinetic studies on carbamazepine in volunteers and in epileptic patients, in Schneider, Janz, Gardner-Thorpe, Meinardi and Sherwin (Eds) Clinical Pharmacology of Anti-epileptic Drugs, p. 166–179 (Springer-Verlag, Berlin 1975).

    Chapter  Google Scholar 

  • Neuvonen, P.J.; Pentilla, O.; Lehtovaara, R. and Aho, K.: Effect of antiepileptic drugs on the elimination of various tetracycline derivatives. European Journal of Clinical Pharmacology 9: 147–154 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Oesch, F.: Mammalian epoxide hydrases: inducible enzymes catalysing the inactivation of carcinogenic and cytotoxic metabolites derived from aromatic and olefinic compounds. Xenobiotica 3: 305–340 (1973).

    Article  PubMed  CAS  Google Scholar 

  • Palmer, L.; Bertilsson, L.; Collste, P. and Rawlins, M.: Quantitative determination of carbamazepine in plasma by mass fragmentography. Clinical Pharmacology and Therapeutics 14: 827–832 (1973).

    PubMed  CAS  Google Scholar 

  • Parsonage, M.: Treatment with carbamazepine: Adults; in Penry and Daly (Eds) Advances in Neurology, vol.11, p. 221–234 (Raven Press, New York 1975).

    Google Scholar 

  • Penttila, O.; Neuvonen, P.J.; Aho, K. and Lehtovaara, R.: Interaction between doxycycline and some antiepileptic drugs. British Medical Journal 2: 470–472 (1974).

    Article  PubMed  CAS  Google Scholar 

  • Pippenger, C.E.; Paris-Kutt, H.; Penry, J.K. and Daly, D.: Proficiency testing in determinations of antiepileptic drugs. Journal of Analytical Toxicology 1: 118–122 (1977).

    CAS  Google Scholar 

  • Pitlick, W.H.; Levy, R.H.; Troupin, A.S. and Green, J.R.: Pharmacokinetic model to describe self induced decreases in steadystate concentrations of carbamazepine. Journal of Pharmaceutical Sciences 65: 462–463 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Pynnonen, S. and Sillanpaa, M.: Carbamazepine in mother’s milk. Lancet 2: 563 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Pynnonen, S.; Sillanpaa, M.; Frey, H. and Iisalo, E.: Carbamazepine and its 10, 11-epoxide in children and adults with epilepsy. European Journal of Clinical Pharmacology 11: 129–133 (1977).

    Article  PubMed  CAS  Google Scholar 

  • Rane, A.; Bertilsson, L. and Palmer, L.: Disposition of placentally transferred carbamazepine (Tegretol ®) in the newborn. European Journal of Clinical Pharmacology 8: 283–284 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Rane, A.; Hojer, B. and Wilson, J.T.: Kinetics of carbamazepine and its 10, 11-epoxide metabolite in children. Clinical Pharmacology and Therapeutics 19: 276–283 (1976).

    PubMed  CAS  Google Scholar 

  • Rane, A.; Shand, D.G. and Wilkinson, G.R.: Disposition of carbamazepine and its 10, 11 -epoxide metabolite in the isolated perfused rat liver. Drug Metabolism and Disposition 5: 179–194 (1977).

    PubMed  CAS  Google Scholar 

  • Raskin, N.H.; Levinson, S.A.; Hoffman, P.M.; Pickett, J.B.E. and Fields, H.L.: Postsympathectomy neuralgia: Amelioration with diphenylhydantoin and carbamazepine. American Journal of Surgery 128: 75–78 (1974).

    Article  PubMed  CAS  Google Scholar 

  • Rasmussen, P. and Riishede, J.: Facial pain treated with carbamazepine (Tegretol ®). Acta Neurologia Scandinavica 46: 385–408 (1970).

    Article  CAS  Google Scholar 

  • Rawlins, M.D.; Collste, P.; Bertilsson, L. and Palmer, L.: Distribution and elimination kinetics of carbamazepine in man. European Journal of Clinical Pharmacology 8: 91–96 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Richens, A. and Dunlop, F.: Serum-phenytoin levels in the management of epilepsy. Lancet 2: 247–248 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Schneider, H.: Carbamazepine: An attempt to correlate serum levels with anti-epileptic and side effects; in Schneider, Janz, Gardner-Thorpe, Meinardi and Sherwin (Eds) Clinical Pharmacology of Anti-epileptic Drugs, p.151–158 (Springer-Verlag, Berlin 1975a).

    Chapter  Google Scholar 

  • Schneider, H.: Carbamazepine: The influence of other antiepileptic drugs on its serum level; in Schneider, Janz, Gardner-Thorpe, Meinardi and Sherwin (Eds) Clinical Pharmacology of Antiepileptic Drugs, p. 189–195 (Springer-Verlag, Berlin 1975b).

    Chapter  Google Scholar 

  • Simonsen, N.; Olsen, P.Z.; Kuhl, V.; Lund, M. and Wendelboe, J.: A comparative controlled study between carbamazepine and diphenylhydantoin in psychomotor epilepsy. Epilepsia 17: 169–176 (1976).

    Article  PubMed  CAS  Google Scholar 

  • Strandjord, R.E. and Johannessen, S.I.: A preliminary study of serum carbamazepine levels in healthy subjects and in patients with epilepsy; in Schneider, Janz, Gardner-Thorpe, Meinardi and Sherwin (Eds) Clinical Pharmacology of Anti-epileptic Drugs, p. 181–188 (Springer-Verlag, Berlin 1975).

    Chapter  Google Scholar 

  • Troupin, A.S.; Green, J.R. and Halpern, L.M.: Carbamazepine (Tegretol) as an anticonvulsant — A controlled double-blind comparison with diphenylhydantoin (Dilantin). Acta Neurologica Scandinavica, Suppl. 60: 13–26 (1975).

    Article  PubMed  CAS  Google Scholar 

  • Wagner, J.G.; Northam, J.I.; Alway, C.D. and Carpenter, O.S.: Blood levels of drug at the equilibrium state after multiple dosing. Nature 207: 1301–1302 (1965).

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bertilsson, L. Clinical Pharmacokinetics of Carbamazepine. Clin Pharmacokinet 3, 128–143 (1978). https://doi.org/10.2165/00003088-197803020-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-197803020-00003

Keywords

Navigation